Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis.

Literature DB >> 15965586

Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis.

Barbara Borroni¹, Daniela Perani, Marcella Broli, Francesca Colciaghi, Valentina Garibotto, Barbara Paghera, Chiara Agosti, Raffaele Giubbini, Monica Di Luca, Alessandro Padovani.

Abstract

Platelet Amyloid Precursor Protein ratio of different abnormal forms and 99mTc-ECD SPECT perfusion analysis were evaluated in Mild Cognitive Impairment (MCI) subjects who progressed to Alzheimer Disease (AD) and in stable MCI. We report that their combined evaluation increases the discriminative power of the analysis in identifying presymptomatic AD. The positive predictive value of these combined markers in identifying progressive MCI was 0.87, and the negative predictive value was 0.90. This observation suggests that the interplay of different markers should be considered for enhancing diagnostic accuracy of pre-clinical AD.

Entities: Disease Gene

Mesh：

Substances：

Year: 2005 PMID： 15965586 DOI： 10.1007/s00415-005-0867-z

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

10 in total

1. Mild cognitive impairment: clinical characterization and outcome.

Authors: R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal: Arch Neurol Date: 1999-03

2. European Association of Nuclear Medicine procedure guidelines for brain perfusion SPET using (99m)Tc-labelled radiopharmaceuticals.

Authors: K Tatsch; S Asenbaum; P Bartenstein; A Catafau; C Halldin; L S Pilowsky; A Pupi
Journal: Eur J Nucl Med Mol Imaging Date: 2002-10 Impact factor: 9.236

3. Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment.

Authors: Chaorui Huang; Lars-Olof Wahlund; Ove Almkvist; Dagmawi Elehu; Leif Svensson; Tomas Jonsson; Bengt Winblad; Per Julin
Journal: Neuroimage Date: 2003-07 Impact factor: 6.556

4. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD.

Authors: A Padovani; L Pastorino; B Borroni; F Colciaghi; L Rozzini; R Monastero; J Perez; C Pettenati; M Mussi; G Parrinello; E Cottini; G L Lenzi; M Trabucchi; F Cattabeni; M Di Luca
Journal: Neurology Date: 2001-12-26 Impact factor: 9.910

5. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Authors: M Riemenschneider; N Lautenschlager; S Wagenpfeil; J Diehl; A Drzezga; A Kurz
Journal: Arch Neurol Date: 2002-11

6. Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease.

Authors: Nobuyuki Okamura; Hiroyuki Arai; Masahiro Maruyama; Makoto Higuchi; Toshifumi Matsui; Haruko Tanji; Takashi Seki; Hisao Hirai; Hiroshi Chiba; Masatoshi Itoh; Hidetada Sasaki
Journal: Am J Psychiatry Date: 2002-03 Impact factor: 18.112

Review 7. Mild cognitive impairment: directions for future research.

Authors: C A Luis; D A Loewenstein; A Acevedo; W W Barker; R Duara
Journal: Neurology Date: 2003-08-26 Impact factor: 9.910

8. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study.

Authors: Barbara Borroni; Francesca Colciaghi; Carlo Caltagirone; Luca Rozzini; Laura Broglio; Flaminio Cattabeni; Monica Di Luca; Alessandro Padovani
Journal: Arch Neurol Date: 2003-12

9. Preclinical prediction of Alzheimer's disease using SPECT.

Authors: K A Johnson; K Jones; B L Holman; J A Becker; P A Spiers; A Satlin; M S Albert
Journal: Neurology Date: 1998-06 Impact factor: 9.910

10. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Authors: K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel
Journal: Neurology Date: 2002-08-27 Impact factor: 9.910

10 in total

12 in total

Review 1. Platelets and Alzheimer's disease: Potential of APP as a biomarker.

Authors: Geneviève Evin; Qiao-Xin Li
Journal: World J Psychiatry Date: 2012-12-22

2. (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease.

Authors: D P Devanand; Ronald L Van Heertum; Lawrence S Kegeles; Xinhua Liu; Zong Hao Jin; Gnanavalli Pradhaban; Henry Rusinek; Mali Pratap; Gregory H Pelton; Isak Prohovnik; Yaakov Stern; J John Mann; Ramin Parsey
Journal: Am J Geriatr Psychiatry Date: 2010-11 Impact factor: 4.105

Review 10. Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?

Authors: S Gauthier; H Zhang; K P Ng; T A Pascoal; P Rosa-Neto
Journal: Transl Neurodegener Date: 2018-05-31 Impact factor: 8.014

Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis.

1. Mild cognitive impairment: clinical characterization and outcome.

2. European Association of Nuclear Medicine procedure guidelines for brain perfusion SPET using (99m)Tc-labelled radiopharmaceuticals.

3. Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment.

4. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD.

5. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

6. Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease.

Review 7. Mild cognitive impairment: directions for future research.

8. Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study.

9. Preclinical prediction of Alzheimer's disease using SPECT.

10. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Review 1. Platelets and Alzheimer's disease: Potential of APP as a biomarker.

2. (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease.

3. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease.

4. Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer's disease.

5. Effects of oxidative stress on amyloid precursor protein processing in rat and human platelets.

Review 6. Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease.

7. White matter hypoperfusion and damage in dementia: post-mortem assessment.

Review 8. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease.

Review 9. Cerebrovascular disease in ageing and Alzheimer's disease.

Review 10. Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?